This finding supports a recent study showing an essential such rolefor IL-17A in remodeling, but not in the development of autoimmunemyocarditis.19 This study,together with ours, indicated that the late remodeling–specific effect ofIL-17A is a potential therapeutic target for preventing the development of chronicheart failure from postmyocarditis and post-MI cardiac remodeling. Here, IL17A is linked to myocardial infarction.